Danielle M Smith1, Carol Christensen2, Dana van Bemmel2, Nicolette Borek2, Bridget Ambrose2, Gladys Erives2, Raymond Niaura3, Kathryn C Edwards4, Cassandra A Stanton4, Benjamin C Blount5, Lanqing Wang5, Jun Feng5, Jeffery M Jarrett6, Cynthia D Ward6, Dorothy Hatsukami7, Stephen S Hecht7, Heather L Kimmel8, Mark Travers1, Andrew Hyland1, Maciej L Goniewicz1. 1. Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2. Office of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, USA. 3. Department of Social and Behavioral Sciences, College of Global Public Health, New York University, New York, NY, USA. 4. Behavioral Health & Health Policy Practice, Westat, Rockville, MD, USA. 5. Tobacco and Volatiles Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. 6. Inorganic and Radiation Analytical Toxicology Branch, Division of Laboratory Sciences, Centers for Disease Control (CDC), Atlanta, GA, USA. 7. University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA. 8. Epidemiology Research Branch, National Institute of Drug Abuse (NIDA), Bethesda, MD, USA.
Abstract
INTRODUCTION: Concurrent use of tobacco cigarettes and e-cigarettes ("dual use") is common among tobacco users. Little is known about differences in demographics and toxicant exposure among subsets of dual users. AIMS AND METHODS: We analyzed data from adult dual users (current every/some day users of tobacco cigarettes and e-cigarettes, n = 792) included in the PATH Study Wave 1 (2013-2014) and provided urine samples. Samples were analyzed for biomarkers of exposure to nicotine and selected toxicants (tobacco-specific nitrosamine NNK [NNAL], lead, cadmium, naphthalene [2-naphthol], pyrene [1-hydroxypyrene], acrylonitrile [CYMA], acrolein [CEMA], and acrylamide [AAMA]). Subsets of dual users were compared on demographic, behavioral, and biomarker measures to exclusive cigarette smokers (n = 2411) and exclusive e-cigarette users (n = 247). RESULTS: Most dual users were predominant cigarette smokers (70%), followed by daily dual users (13%), non-daily concurrent dual users (10%), and predominant vapers (7%). Dual users who smoked daily showed significantly higher biomarker concentrations compared with those who did not smoke daily. Patterns of e-cigarette use had little effect on toxicant exposure. Dual users with high toxicant exposure were generally older, female, and smoked more cigarettes per day. Dual users who had low levels of biomarkers of exposure were generally younger, male, and smoked non-daily. CONCLUSIONS: In 2013-2014, most dual users smoked cigarettes daily and used e-cigarettes occasionally. Cigarette smoking appears to be the primary driver of toxicant exposure among dual users, with little-to-no effect of e-cigarette use on biomarker levels. Results reinforce the need for dual users to stop smoking tobacco cigarettes to reduce toxicant exposure. IMPLICATIONS: With considerable dual use of tobacco cigarettes and e-cigarettes in the United States, it is important to understand differences in toxicant exposure among subsets of dual users, and how these differences align with user demographics. Findings suggest most dual users smoke daily and use e-cigarettes intermittently. Low exposure to toxicants was most common among younger users, males, and intermittent smokers; high exposure to toxicants was most common among older users, females, and heavier cigarette smokers. Results underscore the heterogeneity occurring within dual users, and the need to quit smoking cigarettes completely in order to reduce toxicant exposure.
INTRODUCTION: Concurrent use of tobacco cigarettes and e-cigarettes ("dual use") is common among tobacco users. Little is known about differences in demographics and toxicant exposure among subsets of dual users. AIMS AND METHODS: We analyzed data from adult dual users (current every/some day users of tobacco cigarettes and e-cigarettes, n = 792) included in the PATH Study Wave 1 (2013-2014) and provided urine samples. Samples were analyzed for biomarkers of exposure to nicotine and selected toxicants (tobacco-specific nitrosamine NNK [NNAL], lead, cadmium, naphthalene [2-naphthol], pyrene [1-hydroxypyrene], acrylonitrile [CYMA], acrolein [CEMA], and acrylamide [AAMA]). Subsets of dual users were compared on demographic, behavioral, and biomarker measures to exclusive cigarette smokers (n = 2411) and exclusive e-cigarette users (n = 247). RESULTS: Most dual users were predominant cigarette smokers (70%), followed by daily dual users (13%), non-daily concurrent dual users (10%), and predominant vapers (7%). Dual users who smoked daily showed significantly higher biomarker concentrations compared with those who did not smoke daily. Patterns of e-cigarette use had little effect on toxicant exposure. Dual users with high toxicant exposure were generally older, female, and smoked more cigarettes per day. Dual users who had low levels of biomarkers of exposure were generally younger, male, and smoked non-daily. CONCLUSIONS: In 2013-2014, most dual users smoked cigarettes daily and used e-cigarettes occasionally. Cigarette smoking appears to be the primary driver of toxicant exposure among dual users, with little-to-no effect of e-cigarette use on biomarker levels. Results reinforce the need for dual users to stop smoking tobacco cigarettes to reduce toxicant exposure. IMPLICATIONS: With considerable dual use of tobacco cigarettes and e-cigarettes in the United States, it is important to understand differences in toxicant exposure among subsets of dual users, and how these differences align with user demographics. Findings suggest most dual users smoke daily and use e-cigarettes intermittently. Low exposure to toxicants was most common among younger users, males, and intermittent smokers; high exposure to toxicants was most common among older users, females, and heavier cigarette smokers. Results underscore the heterogeneity occurring within dual users, and the need to quit smoking cigarettes completely in order to reduce toxicant exposure.
Authors: Ron Borland; Krista Murray; Shannon Gravely; Geoffrey T Fong; Mary E Thompson; Ann McNeill; Richard J O'Connor; Maciej L Goniewicz; Hua-Hie Yong; David T Levy; Bryan W Heckman; K Michael Cummings Journal: Addiction Date: 2019-04-02 Impact factor: 6.526
Authors: Andrew A Strasser; Valentina Souprountchouk; Amanda Kaufmann; Sonja Blazekovic; Frank Leone; Neal L Benowitz; Robert A Schnoll Journal: Tob Regul Sci Date: 2016-10
Authors: Andrew Hyland; Bridget K Ambrose; Kevin P Conway; Nicolette Borek; Elizabeth Lambert; Charles Carusi; Kristie Taylor; Scott Crosse; Geoffrey T Fong; K Michael Cummings; David Abrams; John P Pierce; James Sargent; Karen Messer; Maansi Bansal-Travers; Ray Niaura; Donna Vallone; David Hammond; Nahla Hilmi; Jonathan Kwan; Andrea Piesse; Graham Kalton; Sharon Lohr; Nick Pharris-Ciurej; Victoria Castleman; Victoria R Green; Greta Tessman; Annette Kaufman; Charles Lawrence; Dana M van Bemmel; Heather L Kimmel; Ben Blount; Ling Yang; Barbara O'Brien; Cindy Tworek; Derek Alberding; Lynn C Hull; Yu-Ching Cheng; David Maklan; Cathy L Backinger; Wilson M Compton Journal: Tob Control Date: 2016-08-08 Impact factor: 7.552
Authors: Lion Shahab; Maciej L Goniewicz; Benjamin C Blount; Jamie Brown; Ann McNeill; K Udeni Alwis; June Feng; Lanqing Wang; Robert West Journal: Ann Intern Med Date: 2017-02-07 Impact factor: 25.391
Authors: Pavel N Lizhnyak; Brendan Noggle; Lai Wei; Jeffery Edmiston; Elizabeth Becker; Ryan A Black; Mohamadi Sarkar Journal: Harm Reduct J Date: 2022-08-17
Authors: Gal Cohen; Nicholas I Goldenson; Patrick C Bailey; Stephanie Chan; Saul Shiffman Journal: Nicotine Tob Res Date: 2021-11-05 Impact factor: 4.244